Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bruker (BRKR) Gains from Sales and Divestitures (2016 - 2025)

Bruker (BRKR) has disclosed Gains from Sales and Divestitures for 13 consecutive years, with $299973.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Sales and Divestitures rose 10.5% year-over-year to $299973.0, compared with a TTM value of $299973.0 through Dec 2025, up 10.5%, and an annual FY2025 reading of $299973.0, up 10.5% over the prior year.
  • Gains from Sales and Divestitures was $299973.0 for Q4 2025 at Bruker, up from $271477.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $299973.0 in Q4 2025 and bottomed at $266395.0 in Q4 2023.
  • Average Gains from Sales and Divestitures over 4 years is $278804.6, with a median of $275082.0 recorded in 2022.
  • The sharpest move saw Gains from Sales and Divestitures dropped 5.23% in 2023, then increased 10.5% in 2025.
  • Year by year, Gains from Sales and Divestitures stood at $281096.0 in 2022, then fell by 5.23% to $266395.0 in 2023, then grew by 1.91% to $271477.0 in 2024, then increased by 10.5% to $299973.0 in 2025.
  • Business Quant data shows Gains from Sales and Divestitures for BRKR at $299973.0 in Q4 2025, $271477.0 in Q4 2024, and $266395.0 in Q4 2023.